A Phase 3, Multicentre, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy
The main purpose of this study is to compare maintenance treatment with avelumab plus best
supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in
patients with locally advanced or metastatic urothelial cancer that did not worsen during or
following completion of first-line chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society